^
    Back
    Association details:
    Biomarker:IL6-L
    Cancer:Renal Cell Carcinoma
    Drug:pazopanib (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Am J Clin Oncol
    Title:

    Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study)

    Published date:
    05/27/2020
    Excerpt:
    Low baseline levels of IL-6, IL-8, HGF, and osteopontin were found to be significantly associated with objective response. In addition, patients with low baseline levels of HGF showed longer progression-free survival and overall survival, whereas patients with low baseline levels of IL-8 showed longer overall survival. Changes in levels of selected CAFs were associated with response/resistance to pazopanib in mRCC patients.
    DOI:
    10.1097/COC.0000000000000719
    Trial ID:
    PIPELINE